LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

LLY

1,013.58

-0.49%↓

JNJ

229.36

-0.3%↓

ABBV

212.75

-0.41%↓

UNH

383.38

-1.52%↓

AZN

187.36

+1.46%↑

Search

Rhythm Pharmaceuticals Inc

Затворен

СекторЗдравеопазване

90.51 3.71

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

86.37

Максимум

90.55

Ключови измерители

By Trading Economics

Приходи

-8.1M

-56M

Продажби

2.9M

60M

EPS

-0.83

Марж на печалбата

-92.559

Служители

414

EBITDA

-9.7M

-52M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+57.83% upside

Дивиденти

By Dow Jones

Следващи печалби

4.08.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

151M

6B

Предишно отваряне

86.8

Предишно затваряне

90.51

Настроения в новините

By Acuity

100%

0%

329 / 345 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bearish Evidence

Rhythm Pharmaceuticals Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

19.05.2026 г., 20:36 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5 Billion

19.05.2026 г., 23:47 ч. UTC

Пазарно говорене

Nikkei May Decline as Concerns About Energy, Material Costs Persists -- Market Talk

19.05.2026 г., 23:34 ч. UTC

Пазарно говорене

Gold Edges Higher on Possible Technical Recovery -- Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене
Печалби

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 23:28 ч. UTC

Пазарно говорене
Печалби

F&P Healthcare's Outlook Key for Investors -- Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

19.05.2026 г., 23:10 ч. UTC

Пазарно говорене

Kiwi Property's Dividend Growth Reliant on Several Factors -- Market Talk

19.05.2026 г., 22:02 ч. UTC

Печалби

ZTO Express (Cayman): Di Xu to Resign From Board

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Adj EPS 43c >ZTO

19.05.2026 г., 22:01 ч. UTC

Печалби

ZTO Express (Cayman) 1Q EPS 39c >ZTO

19.05.2026 г., 22:00 ч. UTC

Печалби

ZTO Express (Cayman) 1Q Rev $1.93B >ZTO

19.05.2026 г., 21:37 ч. UTC

Печалби

Cracks Are Starting to Appear in the Chip Stock Rally -- Barrons.com

19.05.2026 г., 21:31 ч. UTC

Придобивния, сливания и поглъщания

How NextEra Can Fix Dominion's Strange AI Problem -- Barrons.com

19.05.2026 г., 21:01 ч. UTC

Печалби

Home Depot Beats Earnings Estimates as Shoppers Defy Inflation Fears. The Stock Advances. -- Barrons.com

19.05.2026 г., 20:58 ч. UTC

Печалби

These Stocks Are Today's Movers: CoreWeave, Nvidia, Home Depot, Akamai, Agilysys, Micron, and More -- Barrons.com

19.05.2026 г., 20:46 ч. UTC

Горещи акции

Stocks to Watch Recap: ServiceNow, Home Depot, CoreWeave -- WSJ

19.05.2026 г., 20:43 ч. UTC

Пазарно говорене

Canada 30-Year Yield Hits Highest Level Since 2010 -- Market Talk

19.05.2026 г., 20:34 ч. UTC

Печалби

James Hardie Industries Sees FY27 Sales $5.25B-$5.41B >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries: Targeting Pro Forma Adjusted EBITDA Growth of 4% to 8% in FY27 >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q EPS 5c >JHX

19.05.2026 г., 20:32 ч. UTC

Печалби

James Hardie Industries 4Q Sales $1.4B >JHX

19.05.2026 г., 20:21 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Buy Empower Semiconductor for $1.5B

19.05.2026 г., 20:18 ч. UTC

Пазарно говорене

Canada CPI Data Has Accounting Quirk Related to Travel Tours -- Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

Global Forex and Fixed Income Roundup: Market Talk

19.05.2026 г., 20:13 ч. UTC

Пазарно говорене

'Hard to Square' Canada Rate Hikes Expectations Given Mild Core -- Market Talk

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Deal Further Advances Position as Strategic, System-Level Grid-To-Core Power Partner for Hyperscalers, AI Silicon Developers >ADI

19.05.2026 г., 20:03 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices: Phillips Will Continue Leading IVR Technology Efforts as Part of ADI >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices Will Acquire Empower in All-Cash Transaction for $1.5 B >ADI

19.05.2026 г., 20:02 ч. UTC

Придобивния, сливания и поглъщания

Analog Devices to Acquire Empower Semiconductor, Expanding Its Next-Generation High-Density Power Portfolio for the AI Era

19.05.2026 г., 19:23 ч. UTC

Пазарно говорене

Oil Futures Slip With Market Back on U.S.-Iran Deal Watch -- Market Talk

Сравнение с други в отрасъла

Ценова промяна

Rhythm Pharmaceuticals Inc Прогноза

Ценова цел

By TipRanks

57.83% нагоре

12-месечна прогноза

Среден 137.64 USD  57.83%

Висок 158 USD

Нисък 105 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Rhythm Pharmaceuticals Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

14

Купи

0

Задържане

0

Продай

Техническа оценка

By Trading Central

60 / 65.58Подкрепа & съпротива

Краткосрочен план

Strong Bearish Evidence

Средносрочен план

Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

329 / 345 Класиране в Здравеопазване

Настроения в новините

Много силни мечи доказателства

Волатилност

Под средното

Обем новини (RCV)

Под средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat